Education
About Us
Working with TipRanks
Follow Us
Fulcrum Therapeutics (FULC)
NASDAQ:FULC
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 80.00M | $ 2.81M | $ 6.34M | $ 19.16M |
| Gross Profit | $ -1.39M | $ 78.41M | $ 2.81M | $ -70.44M | $ -50.54M |
| Operating Income | $ -84.77M | $ -21.90M | $ -110.66M | $ -112.56M | $ -81.05M |
| EBITDA | $ -73.49M | $ -18.24M | $ -108.49M | $ -109.72M | $ -78.54M |
| Net Income | $ -74.88M | $ -9.72M | $ -97.33M | $ -109.87M | $ -80.85M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 352.31M | $ 241.02M | $ 236.22M | $ 202.92M | $ 218.16M |
| Total Assets | $ 366.28M | $ 260.72M | $ 257.69M | $ 226.69M | $ 235.00M |
| Total Debt | $ 6.44M | $ 8.63M | $ 10.82M | $ 13.42M | $ 0.00 |
| Net Debt | $ -191.09M | $ -49.58M | $ -14.74M | $ -21.68M | $ -35.41M |
| Total Liabilities | $ 17.28M | $ 17.68M | $ 22.50M | $ 27.74M | $ 23.46M |
| Stockholders' Equity | $ 349.00M | $ 243.03M | $ 235.19M | $ 198.94M | $ 211.54M |
| Cash Flow | |||||
| Free Cash Flow | $ -60.38M | $ -2.50M | $ -91.47M | $ -99.01M | $ -80.19M |
| Operating Cash Flow | $ -60.06M | $ -2.22M | $ -90.97M | $ -97.05M | $ -78.48M |
| Investing Cash Flow | $ 30.72M | $ 32.23M | $ -36.69M | $ 12.41M | $ -129.67M |
| Financing Cash Flow | $ 168.67M | $ 2.75M | $ 118.12M | $ 84.32M | $ 186.51M |